Marinus Pharma (MRNS) Tops Q2 EPS by 11c

Marinus Pharma (NASDAQ: MRNS) reported Q2 EPS of ($0.61), $0.11 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $6.08 million versus the consensus estimate of $5.71 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal